Response assessment by CXCR4, TP53, TERT, and ARID1A mutational status in patients with WM with MYD88MUT
| . | CXCR4WT (n = 137) . | CXCR4MUT (n = 53) . | CXCR4FS (n = 26) . | CXCR4NS (n = 27) . | TP53WT (n = 142) . | TP53MUT (n = 48) . | TERTWT (n = 171) . | TERTMUT (n = 19) . | ARID1AWT (n = 158) . | ARID1AMUT (n = 32) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Best overall response, n (%) | ||||||||||
| CR | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| VGPR | 51 (37.2) | 9 (17.0) | 5 (19.2) | 4 (14.8) | 48 (33.8) | 12 (25.0) | 58 (33.9) | 2 (10.5) | 52 (32.9) | 8 (25.0) |
| PR | 64 (46.7) | 30 (56.6) | 15 (57.7) | 15 (55.6) | 71 (50.0) | 23 (47.9) | 85 (49.7) | 9 (47.4) | 77 (48.7) | 17 (53.1) |
| MR | 16 (11.7) | 10 (18.9) | 4 (15.4) | 6 (22.2) | 16 (11.3) | 10 (20.8) | 20 (11.7) | 6 (31.6) | 21 (13.3) | 5 (15.6) |
| SD | 3 (2.2) | 3 (5.7) | 2 (7.7) | 1 (3.7) | 4 (2.8) | 2 (4.2) | 5 (2.9) | 1 (5.3) | 6 (3.8) | 0 (0.0) |
| PD | 2 (1.5) | 1 (1.9) | 0 (0.0) | 1 (3.7) | 2 (1.4) | 1 (2.1) | 2 (1.2) | 1 (5.3) | 2 (1.3) | 1 (3.1) |
| NE | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (3.1) |
| VGPR or better | 51 (37.2) | 9 (17.0) | 5 (19.2) | 4 (14.8) | 48 (33.8) | 12 (25.0) | 58 (33.9) | 2 (10.5) | 52 (32.9) | 8 (25.0) |
| Major response | 115 (83.9) | 39 (73.6) | 20 (76.9) | 19 (70.4) | 119 (83.8) | 35 (72.9) | 143 (83.6) | 11 (57.9) | 129 (81.7) | 25 (78.1) |
| Time to response, median (min, max), mo | ||||||||||
| VGPR or CR | 8.4 (1.9, 50.0) | 11.1 (2.8, 46.0) | 11.1 (2.8, 26.0) | 13.9 (9.4, 46.0) | 9.3 (1.9, 50.0) | 11.1 (3.0, 46.9) | 9.3 (1.9, 50.0) | 34.1 (22.2, 46.0) | 9.8 (1.9, 49.9) | 10.7 (2.8, 46.0) |
| Major response | 2.8 (0.9, 49.8) | 4.6 (1.0, 49.8) | 6.6 (1.8, 49.8) | 3.7 (1.0, 38.7) | 2.9 (0.9, 49.8) | 2.9 (1.0, 13.8) | 2.8 (0.9, 49.8) | 5.6 (1.8, 22.2) | 2.8 (0.9, 49.8) | 3.0 (1.0, 38.7) |
| . | CXCR4WT (n = 137) . | CXCR4MUT (n = 53) . | CXCR4FS (n = 26) . | CXCR4NS (n = 27) . | TP53WT (n = 142) . | TP53MUT (n = 48) . | TERTWT (n = 171) . | TERTMUT (n = 19) . | ARID1AWT (n = 158) . | ARID1AMUT (n = 32) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Best overall response, n (%) | ||||||||||
| CR | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| VGPR | 51 (37.2) | 9 (17.0) | 5 (19.2) | 4 (14.8) | 48 (33.8) | 12 (25.0) | 58 (33.9) | 2 (10.5) | 52 (32.9) | 8 (25.0) |
| PR | 64 (46.7) | 30 (56.6) | 15 (57.7) | 15 (55.6) | 71 (50.0) | 23 (47.9) | 85 (49.7) | 9 (47.4) | 77 (48.7) | 17 (53.1) |
| MR | 16 (11.7) | 10 (18.9) | 4 (15.4) | 6 (22.2) | 16 (11.3) | 10 (20.8) | 20 (11.7) | 6 (31.6) | 21 (13.3) | 5 (15.6) |
| SD | 3 (2.2) | 3 (5.7) | 2 (7.7) | 1 (3.7) | 4 (2.8) | 2 (4.2) | 5 (2.9) | 1 (5.3) | 6 (3.8) | 0 (0.0) |
| PD | 2 (1.5) | 1 (1.9) | 0 (0.0) | 1 (3.7) | 2 (1.4) | 1 (2.1) | 2 (1.2) | 1 (5.3) | 2 (1.3) | 1 (3.1) |
| NE | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (3.1) |
| VGPR or better | 51 (37.2) | 9 (17.0) | 5 (19.2) | 4 (14.8) | 48 (33.8) | 12 (25.0) | 58 (33.9) | 2 (10.5) | 52 (32.9) | 8 (25.0) |
| Major response | 115 (83.9) | 39 (73.6) | 20 (76.9) | 19 (70.4) | 119 (83.8) | 35 (72.9) | 143 (83.6) | 11 (57.9) | 129 (81.7) | 25 (78.1) |
| Time to response, median (min, max), mo | ||||||||||
| VGPR or CR | 8.4 (1.9, 50.0) | 11.1 (2.8, 46.0) | 11.1 (2.8, 26.0) | 13.9 (9.4, 46.0) | 9.3 (1.9, 50.0) | 11.1 (3.0, 46.9) | 9.3 (1.9, 50.0) | 34.1 (22.2, 46.0) | 9.8 (1.9, 49.9) | 10.7 (2.8, 46.0) |
| Major response | 2.8 (0.9, 49.8) | 4.6 (1.0, 49.8) | 6.6 (1.8, 49.8) | 3.7 (1.0, 38.7) | 2.9 (0.9, 49.8) | 2.9 (1.0, 13.8) | 2.8 (0.9, 49.8) | 5.6 (1.8, 22.2) | 2.8 (0.9, 49.8) | 3.0 (1.0, 38.7) |
Patients with CXCR4MUT, TP53MUT, and TERTMUT trended toward lower VGPR + CR rate, lower MRR, and/or longer median time to response than patients with the respective WT alleles.
max, maximum; min, minimum; MR, minor response; NE, not evaluable due to discontinuation before first assessment; PD, progressive disease; SD, stable disease.